Bictegravir-Based Treatment Wins for HIV/HBV Co-Infections
MONTREAL — For individuals infected by both HIV and hepatitis B virus (HBV), the choice of which virus-suppressing therapy to use can make a difference in outcomes, according to 48-week results of the phase III ALLIANCE results reported here. In a head-to-head comparison, fixed doses of either bictegravir, emtricitabine, and tenofovir alafenamide (Biktarvy) or dolutegravir, […]